肥胖与其他癌症
本文综述了超重、肥胖与前列腺癌、血液系统恶性肿瘤及肾癌风险和预后关系的证据,包括剂量反应荟萃分析和个体参与者数据汇总分析。国际癌症研究机构2016年更新认为避免体脂过多可降低多发性骨髓瘤风险的证据充分,而降低前列腺癌死亡或弥漫性大B细胞淋巴瘤风险的证据有限。
要点
- 较高体重指数与晚期前列腺癌风险、前列腺癌死亡率升高及多数血液系统恶性肿瘤亚型生存更差呈剂量反应关系。
- 肾癌证据多基于回顾性数据,支持透明细胞亚型存在肥胖悖论,但人群队列数据显示入组时体重指数较高与肾癌特异性生存更差相关。
- 国际癌症研究机构2016年更新认为避免体脂过多降低多发性骨髓瘤风险的证据充分,降低前列腺癌死亡或弥漫性大B细胞淋巴瘤风险的证据有限。
核心结论
- 这些数据支持成年早期和后期肥胖导致癌症负担增加的证据,但诊断后体重管理作为改善生存策略的手段问题仍待解决。
研究设计与样本
- 综述总结了前列腺癌、血液系统恶性肿瘤和肾癌死亡率的证据,包括队列中罕见终点的汇总分析、剂量反应荟萃分析和个体参与者数据汇总分析。
主要发现
- 较高体重指数与晚期前列腺癌风险增加和前列腺癌死亡率增加相关,并与多数血液系统恶性肿瘤亚型生存更差相关,呈剂量反应关系。
- 肾癌证据主要基于回顾性数据,支持透明细胞变异型患者存在肥胖悖论;然而人群队列数据表明入组时较高体重指数与肾癌特异性生存更差相关。
关键数值与推荐
- 国际癌症研究机构2016年更新将避免体脂过多降低多发性骨髓瘤风险的证据分类为充分。
- 国际癌症研究机构2016年更新发现避免体脂过多降低前列腺癌死亡率或弥漫性大B细胞淋巴瘤风险的证据有限。
局限性
- 肾癌证据主要基于回顾性数据。
- 诊断后体重管理作为改善生存策略的手段问题仍待解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Evidence on overweight, obesity, and an increased risk of cancer continues to accumulate and was updated in the 2016 handbook on weight control from the International Agency for Research on Cancer (IARC). The underlying primary data, together with dose-response meta-analysis and, finally, pooled analysis of individual participant data, add insight into the relation between obesity and cancer risk and prognosis. We summarize the evidence for mortality from prostate cancer, hematologic malignancies, and kidney cancer. Methods We reviewed pooled analysis of rare end points across cohorts, regardless of primary results reported from the individual studies, further reducing risk of publication bias. Of these cancer sites, only kidney cancer was included in the IARC 2002 report, although mortality from prostate cancer and hematologic malignancies was noted in the American Cancer Society prospective cohort study in 2003. The 2016 update from the IARC added details for prostate and hematologic malignancies, classifying the evidence as sufficient to conclude that avoiding excess body fatness lowers the risk of multiple myeloma but found that the evidence for it lowering the risk of prostate cancer mortality or diffuse large B-cell lymphoma was limited. Results A higher body mass index is associated with an increased risk of advanced prostate cancer and prostate cancer mortality and is associated with worse survival in most subtypes of hematologic malignancies, in a dose-response fashion. Evidence for kidney cancer is built mostly on retrospective data, which supports an obesity paradox in patients with the clear cell variant; however, population-based cohort data indicate that a higher cohort-entry body mass index is associated with worse kidney cancer-specific survival. Conclusion Together, these data add support to the evidence for a growing cancer burden caused by adiposity in both early adult and later adult life, yet leave open the question of the means of weight management after diagnosis as a strategy to improve survival.
引用
- Yang L, Drake BF, Colditz GA, et al. Obesity and Other Cancers. J Clin Oncol. 2016. PMID: 27903157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。